Multiple sclerosis among patients with previous diagnosis of leishmaniasis
Abstract
Keywords
Full Text:
PDFReferences
Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Javadian E,
Jafari R, Zahraei-Ramazani AR, Mohebali M. A new focus
of cutaneous leishmaniasis caused by leishmania tropica.
Saudi Med J 23:291-294. 2002.
Desjeux P. Leishmaniasis. Public health aspects and
control. Clin Dermatol 14:417-423, 1996.
Etemadifar M, Abtahi SH. Multiple sclerosis in
Isfahan, Iran: Past, Present and Future. Int J Prevent Med
:301-302, 2012.
Adil SN, Burney IA, Khurshid M. Autoimmune
hemolytic anemia in visceral leishmaniasis. J Pakistan Med
Assoc 49:100-101, 1999.
Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV.
Leishmaniasis, autoimmune rheumatic disease, and antitumor
necrosis factor therapy. Eur Emerg Infect Dis
:956-959, 2009.
Ghebremichael LT, Veith TL, Hamlett JM.
Integrated watershed- and farm-scale modeling framework
for targeting critical source areas while maintaining farm
economic viability. J Environ Manag 114:381-394, 2013.
Louis J, Himmelrich H, Parra-Lopez C, Tacchini-
Cottier F, Launois P. Regulation of protective immunity
against Leishmania major in mice. Curr Opinion Immunol
:459-464, 1998.
Reiner SL, Locksley RM. The regulation of
immunity to leishmania major. Ann Rev Immunol 13:151-
, 1995.
Gaafar A, Veress B, Permin H, Kharazmi A,
Theander TG, el Hassan AM. Characterization of the local
and systemic immune responses in patients with cutaneous
leishmaniasis due to Leishmania major. Clin Immunol
:314-320, 1999.
Miller A, Glass-Marmor L, Abraham M, Grossman
I, Shapiro S, Galboiz Y. Bio-markers of disease activity
and response to therapy in multiple sclerosis. Clin Neurol
Neurosurg 106:249-254, 2004.
Imitola J, Chitnis T, Khoury SJ. Cytokines in
multiple sclerosis: from bench to bedside. Pharmacol
Therap 106:163-177, 2005.
Kolls JK, Linden A. Interleukin-17 family members
and inflammation. Immunity 21:467-476, 2004.
Matsuzaki G, Umemura M. Interleukin-17 as an
effector molecule of innate and acquired immunity against
infections. Microbiol Immunol 51:1139-1147, 2007.
Chen YC, Chen SD, Miao L, Liu ZG, Li W, Zhao
ZX, et al. Serum levels of interleukin (IL)-18, IL-23 and
IL-17 in Chinese patients with multiple sclerosis. J
Neuroimmunol 243:56-60, 2012.
Libbey JE, Cusick MF, Tsunoda I, Fujinami RS.
Antiviral CD8(+) T cells cause an experimental
autoimmune encephalomyelitis-like disease in naive mice.
J Neurovirol 18:45-54, 2012.
Gunderson AJ, Mohammed J, Horvath FJ,
Podolsky MA, Anderson CR, Glick AB. CD8(+) T cells
mediate RAS-induced psoriasis-like skin inflammation
through IFN-gamma. J Invest Dermatol 133:955-963, 2013.
Ortega C, Fernandez AS, Carrillo JM, Romero P,
Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T
lymphocytes from psoriasis skin plaques are cytotoxic
effector cells that secrete Th17-related cytokines. J Leuk
Biol 86:435-443, 2009.
Pourfallah F, Javadian S, Zamani Z, Saghiri R,
Sadeghi S, Zarea B, et al. Evaluation of serum levels of
zinc, copper, iron, and zinc/copper ratio in cutaneous
leishmaniasis. Iranian J Arthropod Borne Dis 3:7-11, 2009.
Khalil M, Riedlbauer B, Langkammer C, Enzinger
C, Ropele S, Stojakovic T, et al. Cerebrospinal fluid
transferrin levels are reduced in patients with early
multiple sclerosis. Mult Scler 20:1569-1577, 2014.
Stephenson E, Nathoo N, Mahjoub Y, Dunn JF,
Yong VW. Iron in multiple sclerosis: roles in
neurodegeneration and repair. Nature Rev Neurol 10:459-
, 2014.
Refbacks
- There are currently no refbacks.